Clinical response to long action propranolol in 40 patients diagnosed with essential tremor with no previous treatment: An open, non-controlled study;Uso do propranolol de ação prolongada em 40 pacientes com tremor essencial e virgens de tratamento: Um ensaio clínico não controlado

Arquivos de Neuro-Psiquiatria

Volumn 62, Issue 1, 2004, Pages 86-90

  Troiano, André R ^a   Teive, Hélio A G ^a,b   Fabiani, Giórgio B ^a   Zavala, Jorge A A ^a   Sá, Daniel S ^a   Germiniani, Francisco M B ^a   Camargo, Carlos Henrique F ^a   Werneck, Lineu C ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b UFPR ^*  (Brazil)

Author keywords

Essential tremor; Long action propranolol; Treatment

Indexed keywords

PROPRANOLOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; ESSENTIAL TREMOR; EVALUATION; FAMILY HISTORY; FEMALE; HUMAN; MALE; RATING SCALE; TREATMENT OUTCOME;

EID: 1842842414     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0004-282x2004000100015     Document Type: Article

References (30)

1. Louis ED, Ottman R, Hauser A. How common is the most common adult movement disorder? Estimates of the prevalence of essential tremor throughout the world. Mov Disord 1998;13:5-10.
2. Gulcher JR, Jonsson P, Kong A, et al. Mapping of a familial essential tremor gene, FET1, to chromosome 3q13. Nature Genet 1997;17:84-87.
3. Higgins JJ, Pho LT, Nee LE. A gene (ETM) for essential tremor maps to chromosome 2p22-p25. Mov Disord 1997;12:859-864.
4. Pagan FL, Butman JA, Dambrosia JM, Hallet M. Evaluation of essential tremor with multi-voxel magnetic resonance spectroscopy. Neurology 2003;60:1344-1347.
5. Koller WC, Hristova A, Brin M. Pharmacologic treatment of essential tremor. Neurology 2000;54(Suppl 4):S30-S38.
6. Calzetti S, Perucca E. The pharmacological management of essential tremor. In Findley LJ, Koller WC (eds). Handbook of tremor disorders. New York: Marcel Dekker 1995.
7. Teravainen H, Fogelholm R, Larsen A. Effect of propranolol on essential tremor. Neurology 1976;26:27-30.
8. Deuschl G, Bain PG, Brin M, Ad Hoc Scientific Committee. Consensus statement of the movement disorders society on tremor. Mov Disord 1998;13:2-23.
9. Nicaretta DH, Pereira JS, Pimentel MLV. Tremor: adaptação de uma escala clínica. Arq Neuropsiquiatr 1997;55:381-386.
10. Mattos JP. Diagnóstico diferencial dos tremores. Arq Neuropsiquiatr 1998;56:320-323.
11. Bain PG. A combined clinical and neurophysiological approach to the study of patients with tremor. J Neurol Neurosurg Psychiatry 1993;69:839-844.
12. Deuschl G, Zimmermann H, Genger H, Lücking CH. Physiologic classification of essential tremor. In Findley LJ, Koller WC (eds). Handbook of tremor disorders, Inc, New York: Marcel Dekker 1995:195-208.
13. Marsden CD, Obeso JA, Rothwell JC. Benign essential tremor is not a single entity. In Yahr MD (ed). Current concepts in Parkinson's disease. Amsterdam: Excerpta Medica 1983;31-46.
14. Bain PG, Findley LJ, Atchinson P, et al. Assessing tremor severity. J Neurol Neurosurg Psychiatry 1993;56:868-873.
15. Bain PG. The clinical measurement of tremor. Mov Disord 1998;13(Suppl 3):77-80.
16. Huber SJ, Paulson GW. Efficacy of alprazolam for essential tremor. Neurology 1988;38:241-243.
17. Pahwa R, Lyons K, Hubble JP, et al. Double-blind controlled trial of gabapentin in essential tremor. Mov Disord. 1998;13:465-467.
18. Muenter MD, Daube JR, Caviness JN, Miller PM. Treatment of essential tremor with methazolamide. Mayo Clin Proc 1991;66:991-997.
19. Factor SA, Friedman JH. The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997;12:483-496.
20. Curran T, Lang AE. Flunarizine in essential tremor. Clin Neuropharmacol 1993;16:460-463.
21. Biary N, Bahou Y, Sofi MA, Thomas W, al Deeb SM. The effect of nimodipine on essential tremor. Neurology 1995;45:1523-1525.
22. Koller WC, Herbster G, Cone S. Clonidine in the treatment of essential tremor. Mov Disord 1986;1:235-237.
23. Mally J, Stone TW. Eficacy of an adenosine antagonist, theophylline, in essential tremor: comparison with placebo and propranolol. J Neurol Sci 1995;132:129-132.
24. Pahwa R, Lyons KE. Mirtazapine in essential tremor: a double-blind, placebo-controlled pilot study. Mov Disord 2003;18:584-587.
25. Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord 1996;11:250-256.
26. Henderson JM, Ghika JA, Van Melle G, Haller E, Einstein R. Botulinum toxin A in non-dystonic tremors. Eur Neurol 1996;36:29-35.
27. Jefferson D, Jenner P, Marsden CD. Beta-adrenoreceptor antagonists in essential tremor. J Neurol Neurosurg Psychiatry 1979;42:904-909.
28. Calzetti S, Sasso E, Baratti M, Fava R. Clinical and computer-based assessment of long-term therapeutic efficacy of propranolol in essential tremor. Acta Neurol Scand 1990;81:392-396.
29. Cleeves L, Findley LJ. Propranolol and propranolol-LA in essential tremor: a double blind comparative study. J Neurol Neurosurg Psychiatry 1988;51:379-384.
30. Koller WC, Royse VL. Time course of a single oral dose of propranolol in essential tremor. Neurology 1985;35:1494-1498.